SCHEMBL212541

SCHEMBL212541

CC(C)(C)OC(=O)NCc1ccc(CNc2c([N+](=O)[O-])c(Cl)nc3ccccc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.55
KMT2A Q03164 2/20 0.47
GAA P10253 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
PKM P14618 1/20 0.43
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
BRD4 O60885 1/20 0.42
NAMPT P43490 2/20 0.42
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 1/20 0.41
RAD52 P43351 1/20 0.41
TOP2A P11388 1/20 0.40
TOP2B Q02880 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29381474 1.00 EGFR (0.55) EGFRKMT2AGAAMEN1NPC1
SCHEMBL212372 0.93 EGFR (0.48) EGFRKMT2AGAAMEN1NPC1
SCHEMBL30024644 0.90 EGFR (0.55) EGFRKMT2AGAAMEN1NPC1
SCHEMBL843596 0.89 BCHE (0.49) EGFRKMT2AGAAMEN1NPC1
SCHEMBL31709400 0.88 EGFR (0.42) EGFRKMT2AGAAMEN1NPC1
SCHEMBL8125697 0.87 BCHE (0.47) KMT2AGAAMEN1NPC1RAB9A
SCHEMBL8137366 0.87 BCHE (0.47) KMT2AGAAMEN1NPC1RAB9A
SCHEMBL5075541 0.87 EGFR (0.56) EGFRKMT2AGAAMEN1PKM
SCHEMBL5075536 0.87 EGFR (0.56) EGFRKMT2AGAAMEN1PKM
SCHEMBL2744402 0.85 MEN1 (0.47) EGFRKMT2AGAAMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744876-B2 Immunomodulator antibody drug conjugates and uses thereof SUTRO BIOPHARMA, INC. (US) 2023-09-05 US disclosed
EP-1948173-B1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2013-07-17 EP disclosed
US-8377957-B2 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20120071463-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS 3M INNOVATIVE PROPERTIES COMPANY 2012-03-22 US disclosed
US-8088790-B2 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221556-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS PFIZER INC. 2009-09-03 US disclosed
EP-1948173-A2 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS Coley Pharmaceutical Group, Inc. (US) 2008-07-30 EP disclosed
WO-2007056112-A2 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221556-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS IFNG, IL2, IRF3 EGFR 3299/4885KMT2A 2108/4885GAA 975/4885
US-11744876-B2 Immunomodulator antibody drug conjugates and uses thereof FCGR1A, FCGR2A, FCGRT EGFR 305/4885KMT2A 2495/4885GAA 544/4885
US-20120071463-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS IFNG, IL2, IRF3 EGFR 3299/4885KMT2A 2108/4885GAA 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.